Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Nasdaq Equity Premium Income ETF vs TG Therapeutics Inc — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $61.1 (market cap $44.49B), while TG Therapeutics Inc trades at $55.24 (market cap $8.16B). The key difference: JPMorgan Nasdaq Equity Premium Income ETF is far larger — about 5.5× TG Therapeutics Inc's market cap, and JPMorgan Nasdaq Equity Premium Income ETF is more actively traded (5,681,789 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Nasdaq Equity Premium Income ETF for 66 Days and TG Therapeutics Inc for 16 Days on average.
| JEPQ | TGTX | |
|---|---|---|
Market Cap | $44.49B | $8.16B |
Volume | 5,681,789 | 1,735,121 |
Sector | Income / Options Overlay | Health |
52-Week High | $61.46 | $59.06 |
52-Week Low | $53.77 | $26.94 |
Typical Hold Time | 66 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPQ trades at $61.07, down 0.33% on the day, with technical indicators showing a bullish moving average signal but neutral oscillators. The ETF's covered-call strategy generates substantial monthly income, with recent dividends ranging from $0.57 to $0.70 per share. Financial media highlights JEPQ's 11% estimated yield and focus on Nasdaq technology exposure, though the strategy limits upside potential during strong bull markets.
JEPQ offers high monthly income through its covered-call approach on Nasdaq-100 stocks, making it attractive for income-focused investors. However, the strategy caps upside growth potential and distributions vary with market volatility. Key risks include concentrated tech exposure and dependence on options market conditions for income generation.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
